Dexamethasone and COVID-19 Inpatient Mortality : Effect of Dexamethasone on Inpatient Mortality Among Hospitalized COVID-19 Patients
This is a non-randomized, non-interventional study that is part of a research collaboration agreement between the US Food and Drug Administration (FDA) and Aetion to use real-world data to advance the understanding and the natural history of COVID-19 in specific patient populations, as well as treatment and diagnostic patterns during the coronavirus disease (COVID-19) pandemic.This study compares inpatient mortality within 28 days among US patients hospitalized with COVID-19 diagnosis or SARS-CoV-2 infection who initiate dexamethasone treatment with a matched cohort of patients with 'standard of care' who are non-users of corticosteroids of interest (dexamethasone, prednisone, methylprednisolone, hydrocortisone). Patients are compared overall and and stratified by COVID-19 severity subgroups..
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
ClinicalTrials.gov - (2023) vom: 18. Apr. Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
610 |
---|
Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: June 15, 2021, Last downloaded: ClinicalTrials.gov processed this data on April 26, 2023, Last updated: April 26, 2023 |
---|
Study ID: |
NCT04926571 |
---|---|
Veröffentlichungen zur Studie: |
|
fisyears: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
CTG007708408 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG007708408 | ||
003 | DE-627 | ||
005 | 20230426010705.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210623s2023 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG007708408 | ||
035 | |a (UBBS_Klinische_Studien)NCT04926571 | ||
035 | |a (UBBS_Klinische_Studien)RQ004-1-20210610 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a Dexamethasone and COVID-19 Inpatient Mortality |b Effect of Dexamethasone on Inpatient Mortality Among Hospitalized COVID-19 Patients |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: June 15, 2021, Last downloaded: ClinicalTrials.gov processed this data on April 26, 2023, Last updated: April 26, 2023 | ||
520 | |a This is a non-randomized, non-interventional study that is part of a research collaboration agreement between the US Food and Drug Administration (FDA) and Aetion to use real-world data to advance the understanding and the natural history of COVID-19 in specific patient populations, as well as treatment and diagnostic patterns during the coronavirus disease (COVID-19) pandemic.This study compares inpatient mortality within 28 days among US patients hospitalized with COVID-19 diagnosis or SARS-CoV-2 infection who initiate dexamethasone treatment with a matched cohort of patients with 'standard of care' who are non-users of corticosteroids of interest (dexamethasone, prednisone, methylprednisolone, hydrocortisone). Patients are compared overall and and stratified by COVID-19 severity subgroups. | ||
650 | 2 | |a Coronavirus Infections | |
650 | 4 | |a Study Type: Observational | |
650 | 4 | |a Recruitment Status: Completed | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2023) vom: 18. Apr. |
773 | 1 | 8 | |g year:2023 |g day:18 |g month:04 |
856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04926571 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
951 | |a AR | ||
952 | |j 2023 |b 18 |c 04 |